The Chinese Covid-19 vaccine triggers the immune response

14:48 21.11.2020Short URL

https://cdnfr1.img.sputniknews.com/img/104380/03/1043800320_0:0:1921:1081_1200x675_80_0_0_e7d4a09606213ef7bf7d82e9c00771b2.jpg

https://fr.sputniknews.com/sante/202011211044807821-un-vaccin-chinois-contre-le-covid-19-declenche-une-reponse-immunitaire/

While a Covid-19 vaccine candidate is being tested in China on volunteers, scientists from China’s biopharmaceutical company Sinovac Biotech indicate that a rapid immune response is being activated at this stage of early clinical and medium-term trials, reports The Lancet. Infectious Diseases.

A candidate vaccine against Covid-19 developed by the Chinese biopharmaceutical company Sinovac Biotech, in a study with the participation of volunteers, has shown its safety and its ability to trigger a rapid immune response. Reviews of initial and mid-term clinical trials have been published in The Lancet Infectious Diseases journal.

The level of antibodies in the volunteers was found to be lower than that of people who recovered from Covid-19. However, this did not affect the vaccine’s ability to protect the human body from the virus, according to the results of the studies. Called CoronaVac, it has been tested on more than 700 healthy adults between the ages of 18 and 59.

A vaccine with two injections

Participants in the trials were injected with two doses of the vaccine 14 days apart. The results obtained demonstrate the product’s effectiveness and its usefulness for emergency treatment during the pandemic, according to one of the authors of the scientific paper, Fengcai Zhu.

He said that to define the duration of immunity after vaccination, further studies should be carried out.

Now, the vaccine candidate is in the third phase of clinical trials to confirm its effectiveness.